Low-Testosterone Replacement Therapies Make Cover of Time Magazine: Are They Safe?
The topic of low testosterone (Low-T) replacement therapy drugs will be discussed, along with securing the coveted cover page, in the August 2014 issue of Time Magazine.
The magazine will feature an article discussing the $2 Billion testosterone drug industry and detailing the safety concerns centered around Low-T replacement medications. This comes as no surprise after the U.S. Food and Drug Administration (FDA) required new label changes on all testosterone replacement therapies to warn consumers about blood clot risks. An FDA panel is set to meet this September to discuss additional concerns over heart attack risks associated with the Low-T products.
The current $2 Billion testosterone market is expected to grow to $5 Billion by 2017. These monetary figures are partly attributed to the aggressive marketing tactics employed by the testosterone drug manufacturers. Manufacturers of these testosterone products are now facing a multitude of lawsuits after the Judicial Panel on Multidistrict Litigation (JPML) entered an order consolidating all cases filed in federal court over alleged injuries involving testosterone products into a Multidistrict Litigation (MDL 2545) pending before The Honorable Judge Matthew F. Kennelly in the Northern District of Illinois.
Schlichter, Bogard & Denton are leaders in the national Low-T Multidistrict Litigation. In early July, Judge Kennelly appointed Kristine Kraft of Schlichter, Bogard & Denton to the Plaintiffs’ Steering Committee, which will oversee and manage the growing number of cases pending against the Low-T manufacturers.
If you or a loved one has suffered injuries after using testosterone products, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements.